Corrections: Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

Errata

This article corrects:

  1. Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response Volume 54, Issue 2, 443–451, Article first published online: 25 July 2011

In the article entitled “Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response” by Zoutendijk etal. (HEPATOLOGY 201;54(2):443-451, the headings in Table 3 are incorrect. In Table 4, the mutation data “S202G, I169T” for Patient 3 is missing. Below are the corrected tables.

Table 3. NA-naïve patients with a partial virological response at week 48. Characteristics of 36 patients with a detectable HBV DNA after 48 weeks of continuous ETV monotherapy
 All patientsResponseWithout responseP value
N=36N=29N=7
Age41±1443±1433±130.13
Gender (male %)30 (83%)26 (90%)4 (57%)0.07
Race   0.09
 Caucasian17 (47%)15 (51%)2 (29%) 
 Asian11 (31%)8 (28%)3 (43%) 
 Other8 (22%)6 (21%)2 (29%) 
HBeAg-positive28 (78%)22 (76%)6 (86%)0.58
Presence of cirrhosis7 (19%)6 (21%)1 (14%)0.70
Follow-up (Months, IQR)27 (19-35)28 (19-35)22 (19-28)0.23
Baseline HBV DNA (Log10 IU/ml)7.7±1.47.5±1.58.2±1.10.31
HBV DNA week 48 (Log10 IU/ml)2.7±1.32.3±1.23.8±0.80.006
HBV DNA decline at week 48 (Log10 IU/ml)5.0±1.35.1±1.34.3±0.80.13
HBV DNA last visit (Log10 IU/ml)  3.0±0.9 
Load >1000 IU/mL at week 4814 (39%)8 (28%)6 (86%)< 0.001
Table 4. Characteristics of four patients developing genotypic mutations to entecavir
 Patient 1Patient 2Patient 3Patient 4
Age (years)26672926
GenderMalemalemaleFemale
At start of entecavir    
 HBeAg statuspositivepositivepositivePositive
 HBV DNA (log10 IU/mL)8.95.77.94.2
 Prior LAM exposureNoYesYesYes
 Prior LAM-resistanceNoYesYesYes
 Baseline LAM-resistanceNoNoNoNo
 HBV GenotypeADAC
Viral load at max. viral suppression (log10 IU/ml)<1.95.32.93.8
Month of resistance4092815
At time of resistance    
 HBV DNA (log10 IU/ml)5.45.36.35.5
 Mutational patternrtM204V, rtL180M, rtI169T, L217RL180M, M204V, V173L, A181T, N236TrtM204V, rtL180M, V173L, S202G, I169TrtM204V, L180M, T184I
 Adverse outcomeNoneNoneNoneNone
 Non-complianceNoNoNoNo
Response to salvage therapy    
 Salvage therapyAddition of tenofovirTenofovir monotherapyAddition of tenofovirTenofovir monotherapy
 Follow-up (months)44185418
 HBV DNA at last F/U (log10IU/ml)< 1.9< 1.9< 1.94.0

The Publisher regrets the errors.

Ancillary